Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

TON - February 2013, Vol 6, No 1

Updated findings from the pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial found robust activity and sustained benefit for the investigational tyrosine kinase inhibitor ponatinib in heavily pretreated patients with accelerated or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL).
TON - February 2013, Vol 6, No 1 published on February 21, 2013 in FDA Updates
Bevacizumab (Avastin; Genentech) received FDA approval on January 23, 2013, for use in combination with fluoropyrimidine-irinotecan–based or fluoropyrimidine-oxaliplatin–based chemotherapy for treating patients with metastatic colorectal cancer (mCRC) with disease that has progressed on a regimen containing first-line bevacizumab.
TON - February 2013, Vol 6, No 1 published on February 21, 2013 in FDA Updates
The US Food and Drug Administration (FDA) approved doxorubicin hydrochloride liposome injection (Sun Pharma Global FZE) for the treatment of patients with ovarian cancer with disease progression after platinum-based chemotherapy and for the treatment of AIDS-related sarcoma in patients after failure of systemic chemotherapy or intolerance to that therapy.
TON - February 2013, Vol 6, No 1 published on February 21, 2013 in From the Editors
Welcome to the first issue of The Oncology Nurse-APN/PA (TON) for 2013. We’ll be publishing 11 issues this year, keeping you up-to-date about what is happening in the world of oncology research and bringing you information that helps you in your day-to-day practice.
TON - February 2013, Vol 6, No 1 published on February 21, 2013 in Noteworthy Numbers
According to the World Health Organization, one-third of all cancer cases are preventable.1 When individuals choose the right health behaviors and avoid exposure to certain environmental risk factors, prevention becomes the most long-term cost-effective approach for curtailing cancer.2 The following statistics examine policy factors and behavioral prevention strategies.
TON - February 2013, Vol 6, No 1 published on February 21, 2013
The Oncology Nurse-APN/PA (TON) asked its online reading community to share their inspiration for entering the oncology field.
TON - February 2013, Vol 6, No 1 published on February 21, 2013
I was astonished at the pace at which the medical world functions when I went through my health crisis facing ovarian cancer 6 years ago.
In patients who have undergone hematopoietic stem cell transplants, genetic factors may influence susceptibility to congestive heart failure related to anthracyclines used prior to transplant, City of Hope researchers found.
Among children with acute myeloid leukemia (AML), the presence of a specific genetic marker known as WT1 SNP rs16754 may be associated with reduced chemotherapy-related toxicity and reduced treatment-related toxic deaths if they are African American or Asian, a phase 2 Children’s Oncology Group trial suggested.
Memorial Sloan-Kettering Cancer Center (MSKCC) researchers showed that cryotherapy given at the time of high-dose melphalan reduced the incidence of severe oral mucositis and the need for pain medicine in patients with multiple myeloma who are undergoing autologous stem cell support.
Page 1 of 3
Results 1 - 10 of 23